Aibotics, Inc. is a biotechnology and wellness technology company focused on advancing psychedelic-based therapies for mental health treatment while expanding into artificial intelligence-driven consumer health products. The company operates at the intersection of pharmaceutical development, digital therapeutics, and AI-powered wellness solutions, targeting conditions such as depression, anxiety, and palliative care. Aibotics leverages partnerships with research institutions and technology providers to support clinical studies and commercialize innovative products in regulated and consumer markets.

The company generates revenue through the distribution of naturally derived psychedelic compounds, such as psilocybin, to universities, researchers, and pharmaceutical companies for clinical and research purposes. Additionally, Aibotics commercializes AI-powered consumer health products, including the Phill Robot, an AI-driven massage device, and the Milkyway, a smart breast milk storage refrigerator. These products are sold directly to consumers and institutions, with potential revenue-sharing agreements tied to sales performance.

The company operates through the following segments.

• Psychedelic Therapeutics: This segment focuses on the research and development of psychedelic compounds for mental health applications. Aibotics supplies active pharmaceutical ingredients, such as psilocybin, to clinical researchers and pharmaceutical developers under supply agreements. The segment also integrates digital therapeutics, including EEG brain cap technology, to measure the neurological effects of psychedelic therapies. Partnerships with entities like Havn Life Sciences support the sourcing and distribution of these compounds.

• AI and Robotics: This segment develops and markets AI-powered consumer health products. The flagship product, Phill Robot, is an AI-driven massage device designed for personalized wellness experiences. The Milkyway, another key product, is a smart refrigerator for breast milk storage, targeting modern parenting needs. These products are positioned in the consumer wellness market and are not regulated as medical devices.

Aibotics occupies a niche position within the rapidly evolving psychedelic therapeutics and consumer health technology industries. In the psychedelic space, the company competes with firms like Compass Pathways, MindMed, and Field Trip Health, which are also advancing clinical research and commercialization of psychedelic-based treatments. Aibotics differentiates itself through its focus on supply chain development, digital therapeutics integration, and strategic partnerships with research institutions. In the AI-driven consumer health segment, the company faces competition from established wellness technology providers but aims to leverage its AI and robotics expertise to capture market share in the growing home wellness sector.

The company serves a diverse customer base across its segments. In psychedelic therapeutics, primary customers include universities, clinical researchers, and pharmaceutical companies engaged in mental health treatment development. Specific partners, such as Havn Life Sciences, support the supply of active pharmaceutical ingredients. In the AI and robotics segment, Aibiotics targets individual consumers seeking advanced wellness solutions, as well as institutions like hospitals and nursing facilities that require large-capacity breast milk storage systems.